within Pharmacolibrary.Drugs.ATC.V;

model V08CB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.004333333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0038,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Iron oxide nanoparticles are superparamagnetic particles used mainly as contrast agents for magnetic resonance imaging (MRI). They are also investigated for use in drug delivery and nanomedicine applications. Some forms such as Ferumoxides (V08CB03) were previously approved but are currently discontinued in several markets due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans following intravenous administration based on published reviews and typical physicochemical behavior of iron oxide nanoparticles, as no specific primary PK study can be identified in the literature.</p><h4>References</h4><ol><li><p>Arami, H, et al., &amp; Krishnan, KM (2015). In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. <i>Chemical Society reviews</i> 44(23) 8576–8607. DOI:<a href=&quot;https://doi.org/10.1039/c5cs00541h&quot;>10.1039/c5cs00541h</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26390044/&quot;>https://pubmed.ncbi.nlm.nih.gov/26390044</a></p></li><li><p>Pai, AB (2019). Iron Oxide Nanoparticle Formulations for Supplementation. <i>Metal ions in life sciences</i> 19 –. DOI:<a href=&quot;https://doi.org/10.1515/9783110527872-012&quot;>10.1515/9783110527872-012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30855107/&quot;>https://pubmed.ncbi.nlm.nih.gov/30855107</a></p></li><li><p>Wang, N, et al., &amp; Gao, M (2025). Iron Homeostasis-Regulated Adaptive Metabolism of PEGylated Ultrasmall Iron Oxide Nanoparticles. <i>ACS nano</i> 19(13) 13381–13398. DOI:<a href=&quot;https://doi.org/10.1021/acsnano.5c01399&quot;>10.1021/acsnano.5c01399</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40135968/&quot;>https://pubmed.ncbi.nlm.nih.gov/40135968</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V08CB03;
